Proband-Only Clinical Exome Sequencing for Neurodevelopmental Disabilities

Se Hee Kim, Borahm Kim, Joon Soo Lee, Heung Dong Kim, Jong Rak Choi, Seung Tae Lee, Hoon Chul Kang

Research output: Contribution to journalArticle

Abstract

Background: Whole exome sequencing on family trios gives the highest diagnostic yield, but high cost limits its application. Here, we performed proband-only clinical exome sequencing in a population of patients with neurodevelopmental disabilities and tested the diagnostic yield. Methods: This observational, retrospective study included 108 unrelated patients with neurodevelopmental disabilities who underwent clinical exome sequencing at the outpatient clinics of the Severance Children's Hospital, Seoul, South Korea, between March 2017 and May 2018. Clinical exome sequencing targeted 4503 disease-causing genes. Results: The overall diagnostic rate was 38.0% (41 of 108) when proband-only clinical exome sequencing was performed without additional parental testing. Four sequence variants were reclassified as likely pathogenic after parental testing, representing an additional 3.7% of the diagnostic yield. The final diagnostic rate was 41.7% (45 of 108). Of 45 patients with genetic abnormalities, a total of 38 sequence variations were detected in 33 (30.6%) patients with five homozygous cases, and 13 chromosomal copy number variants were detected in 12 (11.1%) patients. Novel variants of known causal genes for neurodevelopmental disabilities were detected in 18 (16.7%) patients. These were variants that could be reclassified as likely pathogenic if the de novo nature of the mutation was confirmed after testing of parental samples. Conclusions: Proband-only clinical exome sequencing is a practical diagnostic tool that may be implemented in the clinical setting for patients with neurodevelopmental disabilities. A cost-effective approach to neurodevelopmental disabilities would be a proband-only clinical exome sequencing followed by parental testing of selective candidate variants.

Original languageEnglish
Pages (from-to)47-54
Number of pages8
JournalPediatric Neurology
Volume99
DOIs
Publication statusPublished - 2019 Oct

Fingerprint

Exome
Costs and Cost Analysis
Republic of Korea
Ambulatory Care Facilities
Genes
Observational Studies
Retrospective Studies
Mutation

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Kim, Se Hee ; Kim, Borahm ; Lee, Joon Soo ; Kim, Heung Dong ; Choi, Jong Rak ; Lee, Seung Tae ; Kang, Hoon Chul. / Proband-Only Clinical Exome Sequencing for Neurodevelopmental Disabilities. In: Pediatric Neurology. 2019 ; Vol. 99. pp. 47-54.
@article{4b6a62dbeb4f494a8f53428324bc0de0,
title = "Proband-Only Clinical Exome Sequencing for Neurodevelopmental Disabilities",
abstract = "Background: Whole exome sequencing on family trios gives the highest diagnostic yield, but high cost limits its application. Here, we performed proband-only clinical exome sequencing in a population of patients with neurodevelopmental disabilities and tested the diagnostic yield. Methods: This observational, retrospective study included 108 unrelated patients with neurodevelopmental disabilities who underwent clinical exome sequencing at the outpatient clinics of the Severance Children's Hospital, Seoul, South Korea, between March 2017 and May 2018. Clinical exome sequencing targeted 4503 disease-causing genes. Results: The overall diagnostic rate was 38.0{\%} (41 of 108) when proband-only clinical exome sequencing was performed without additional parental testing. Four sequence variants were reclassified as likely pathogenic after parental testing, representing an additional 3.7{\%} of the diagnostic yield. The final diagnostic rate was 41.7{\%} (45 of 108). Of 45 patients with genetic abnormalities, a total of 38 sequence variations were detected in 33 (30.6{\%}) patients with five homozygous cases, and 13 chromosomal copy number variants were detected in 12 (11.1{\%}) patients. Novel variants of known causal genes for neurodevelopmental disabilities were detected in 18 (16.7{\%}) patients. These were variants that could be reclassified as likely pathogenic if the de novo nature of the mutation was confirmed after testing of parental samples. Conclusions: Proband-only clinical exome sequencing is a practical diagnostic tool that may be implemented in the clinical setting for patients with neurodevelopmental disabilities. A cost-effective approach to neurodevelopmental disabilities would be a proband-only clinical exome sequencing followed by parental testing of selective candidate variants.",
author = "Kim, {Se Hee} and Borahm Kim and Lee, {Joon Soo} and Kim, {Heung Dong} and Choi, {Jong Rak} and Lee, {Seung Tae} and Kang, {Hoon Chul}",
year = "2019",
month = "10",
doi = "10.1016/j.pediatrneurol.2019.02.017",
language = "English",
volume = "99",
pages = "47--54",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",

}

Proband-Only Clinical Exome Sequencing for Neurodevelopmental Disabilities. / Kim, Se Hee; Kim, Borahm; Lee, Joon Soo; Kim, Heung Dong; Choi, Jong Rak; Lee, Seung Tae; Kang, Hoon Chul.

In: Pediatric Neurology, Vol. 99, 10.2019, p. 47-54.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Proband-Only Clinical Exome Sequencing for Neurodevelopmental Disabilities

AU - Kim, Se Hee

AU - Kim, Borahm

AU - Lee, Joon Soo

AU - Kim, Heung Dong

AU - Choi, Jong Rak

AU - Lee, Seung Tae

AU - Kang, Hoon Chul

PY - 2019/10

Y1 - 2019/10

N2 - Background: Whole exome sequencing on family trios gives the highest diagnostic yield, but high cost limits its application. Here, we performed proband-only clinical exome sequencing in a population of patients with neurodevelopmental disabilities and tested the diagnostic yield. Methods: This observational, retrospective study included 108 unrelated patients with neurodevelopmental disabilities who underwent clinical exome sequencing at the outpatient clinics of the Severance Children's Hospital, Seoul, South Korea, between March 2017 and May 2018. Clinical exome sequencing targeted 4503 disease-causing genes. Results: The overall diagnostic rate was 38.0% (41 of 108) when proband-only clinical exome sequencing was performed without additional parental testing. Four sequence variants were reclassified as likely pathogenic after parental testing, representing an additional 3.7% of the diagnostic yield. The final diagnostic rate was 41.7% (45 of 108). Of 45 patients with genetic abnormalities, a total of 38 sequence variations were detected in 33 (30.6%) patients with five homozygous cases, and 13 chromosomal copy number variants were detected in 12 (11.1%) patients. Novel variants of known causal genes for neurodevelopmental disabilities were detected in 18 (16.7%) patients. These were variants that could be reclassified as likely pathogenic if the de novo nature of the mutation was confirmed after testing of parental samples. Conclusions: Proband-only clinical exome sequencing is a practical diagnostic tool that may be implemented in the clinical setting for patients with neurodevelopmental disabilities. A cost-effective approach to neurodevelopmental disabilities would be a proband-only clinical exome sequencing followed by parental testing of selective candidate variants.

AB - Background: Whole exome sequencing on family trios gives the highest diagnostic yield, but high cost limits its application. Here, we performed proband-only clinical exome sequencing in a population of patients with neurodevelopmental disabilities and tested the diagnostic yield. Methods: This observational, retrospective study included 108 unrelated patients with neurodevelopmental disabilities who underwent clinical exome sequencing at the outpatient clinics of the Severance Children's Hospital, Seoul, South Korea, between March 2017 and May 2018. Clinical exome sequencing targeted 4503 disease-causing genes. Results: The overall diagnostic rate was 38.0% (41 of 108) when proband-only clinical exome sequencing was performed without additional parental testing. Four sequence variants were reclassified as likely pathogenic after parental testing, representing an additional 3.7% of the diagnostic yield. The final diagnostic rate was 41.7% (45 of 108). Of 45 patients with genetic abnormalities, a total of 38 sequence variations were detected in 33 (30.6%) patients with five homozygous cases, and 13 chromosomal copy number variants were detected in 12 (11.1%) patients. Novel variants of known causal genes for neurodevelopmental disabilities were detected in 18 (16.7%) patients. These were variants that could be reclassified as likely pathogenic if the de novo nature of the mutation was confirmed after testing of parental samples. Conclusions: Proband-only clinical exome sequencing is a practical diagnostic tool that may be implemented in the clinical setting for patients with neurodevelopmental disabilities. A cost-effective approach to neurodevelopmental disabilities would be a proband-only clinical exome sequencing followed by parental testing of selective candidate variants.

UR - http://www.scopus.com/inward/record.url?scp=85063691275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063691275&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2019.02.017

DO - 10.1016/j.pediatrneurol.2019.02.017

M3 - Article

C2 - 30952489

AN - SCOPUS:85063691275

VL - 99

SP - 47

EP - 54

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

ER -